AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

News provided by

Feb 23, 2024, 22:45 ET

NEW ORLEANS, Feb. 23, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 9, 2024 to file lead plaintiff applications in a securities class action lawsuit against Amylyx Pharmaceuticals, Inc. (NASDAQ-GS: AMLX), if they purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Get Help

Amylyx investors should visit us at https://claimsfiler.com/cases/nasdaq-amlx/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Amylyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had overstated the commercial prospects of its product, RELYVRIO, a treatment used for ALS; (ii) patients were discontinuing RELYVRIO treatment after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) the Company had also overstated RELYVRIO's prescription rate; (v) the Company attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing its prescription data; and (vi) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.

The case is Shih v. Amylyx Pharmaceuticals, Inc., et al., No. 24-cv-00988.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler